| Starts: | Tuesday December 01, 2009 at 8:00am |
|---|---|
| Ends: | Friday December 04, 2009 at 5:00pm |
| Event Type: | Conference |
| Region: | London, United Kingdom |
| Location: |
The Bloomsbury Hotel 16-22 Great Russell Street London, GREATER LONDON WC1B 3NN GB |
| Price: | https://secure.terrapinn.com/V5/rCalc.aspx?E=3137 |
| Website: | http://www.healthnetworkcommunications.com/2009/lsdd |
| Industry: | pharmaceuticals |
| Keywords: | Late Stage, Phase Ii Ib, Phase Iv, Clinical Trials, Pharmaceutical, Biotech, Strategy, Conference, Approved Drug, Safety, Marketed Drugs, Patient, Surveillance, Phase Ii, Risk, Speed, Efficiency |
| Intended For: | late stage, phase IIIb, phase IV, phase II, clinical trials, pharmaceutical, biotech, strategy, conference, approved drug, safety, marketed drugs, risk, patient, speed, efficiency, surveillance |
| Organization: | Health Network Communications |
Late phase drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
As a result, Health Network Communications is delighted to announce the first ever strategic forum addressing the major challenges in conducting strategic and compliant late stage studies.